SpyGlass

SpyGlass

Private
Aliso Viejo, CaliforniaHealthcare & Life Scienceshttps://www.spyglasspharma.com

Last Round

IPO Announced

Feb 5, 2026

Est. Valuation

$510M

Total Funding Raised

$198.5M

Company Overview

SpyGlass Pharma is a healthcare company specializing in ophthalmic devices and drug delivery systems aimed at enhancing vision and eye care for patients with chronic ophthalmic conditions.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

drug delivery platformintraocular lensIOLglaucoma treatmentdrug-eluting implantsustained release medicationocular drug deliverycataract surgerydrug-device combinationglaucoma implantmedicated IOLophthalmic biotechnologyclinical-stage biotechocular hypertensionbimatoprostpatient adherence

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SpyGlass Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

SpyGlass Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
IPO AnnouncedFeb 5, 2026
Series DJun 2, 2025
Series CJul 10, 2023
Series BJan 7, 2021
Series AMay 1, 2019

Key People

Founding team and executive leadership

Glenn Sussman

Co-Founder And CTO

Founding Team

SpyGlass Investors

Notable investors and investment history

InvestorRounds
RA Capital AdvisorsSeries C, Series D
RA Capital ManagementIPO, Series D, Series C
Vertex Ventures HCIPO, Series C, Series D
New Enterprise Associates (NEA)Series B, Series D, Series C, Series A
Gilde HealthcareIPO, Series D
Vensana CapitalIPO, Series C, Series B, Series D
Astoria Health InvestorsIPO

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 10, 2026

    Job posting indicates the company is now publicly traded.

  • Mar 10, 2026

    Lead product is currently enrolling patients in Phase 3 clinical trials.

SpyGlass Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SpyGlass Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SpyGlass's valuation, stock price, and market status.

Firmographic Details

HeadquartersAliso Viejo, California
Employee Range59
Year Founded2020
Last FundingFeb 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.